News and Views
Nature Medicine 14, 495 - 496 (2008)
doi:10.1038/nm0508-495
Bench to bedside: BRCA: From therapeutic target to therapeutic shield
Neil P Shah1
-
Neil P. Shah is in the Department of Hematology/Oncology, University of California, San Francisco, 505 Parnassus Avenue, Suite M1286, Box 1270, San Francisco, California 94143, USA.
e-mail: nshah@medicine.ucsf.edu
Abstract
Three studies examine how resistance to chemotherapy develops in cancers deficient in BRCA1 and BRCA2. The mechanism involves restoration of BRCA1 and BRCA2 activity. Shah examines the implications for the clinic, such as the potential value of continuing treatment with cisplatin and similar agents even after drug resistance develops.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Cisplatin and the sensitive cellNature Medicine News and Views (01 May 2003)
Cancer Crossing over to drug resistanceNature News and Views (28 Feb 2008)
RESEARCH
Disruption of the Fanconi anemia?BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine Article (01 May 2003)
SIGIRR, a negative regulator of Toll-like receptor?interleukin 1 receptor signalingNature Immunology Article (01 Sep 2003)
